New drug combo shows promise for rare lymphoma
NCT ID NCT01808599
First seen Jan 16, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study tested a combination of two drugs, chlorambucil (a chemotherapy pill) and rituximab (an antibody given as a shot under the skin), followed by maintenance rituximab, in 112 people with MALT lymphoma, a slow-growing cancer of the lymph system. The goal was to see how many patients achieved complete remission (no signs of cancer). Participants had either newly diagnosed or relapsed MALT lymphoma that was CD20-positive. The approach aims to control the disease, but ongoing management may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AO SS. Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
-
ARNAS Garibaldi Catania
Catania, Italy
-
Ancona
Ancona, Italy
-
Arcispedale Santa Maria Nuova, Azienda Ospedaliera di Reggio Emilia
Reggio Emilia, Italy
-
Azienda Ospedaliero-Universitaria di Parma
Parma, Italy
-
Azienda Sanitaria AUSL6 Livorno
Livorno, Italy
-
Biella Ospedale degli Infermi
Biella, Italy
-
Centro di Riferimento Oncologico di Aviano
Aviano, Italy
-
Clermont Ferrand CHU Estaing
Estaing, France
-
Créteil Hopital Henri Mondor
Créteil, France
-
Dijon CHU Hopital le Bocage
Dijon, France
-
Ematologia Ospedale Businco (Cagliari)
Cagliari, Italy
-
Ematologia e CTMO Ospedale Bolzano
Bolzano, Italy
-
Genova Ematologia I H San Martino
Genova, Italy
-
Grenoble CHU Pontchaillou
Grenoble, France
-
IOSI - Oncology Institute of Southern Switzerland
Bellinzona, 6500, Switzerland
-
IOV Padova
Padova, Italy
-
IRCCS/CROB Rionero in Vulture
Rionero in Vulture, Italy
-
Istituto Nazionale dei Tumori, Milano
Milan, Italy
-
Istituto Regina Elena, Roma, IFO
Roma, Italy
-
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola
Meldola, Italy
-
Lille CHRU Hopital Claude Dieu
Lille, France
-
Marseille Paoli Calmettes
Marseille, France
-
Milano Ospedale Policlinico
Milan, Italy
-
Montpellier CHU Saint Eloi
Montpellier, France
-
Nantes CHU Hotel Dieu
Nantes, France
-
Nocera
Nocera Umbra, Italy
-
Ospedale Infermi Ematologia Rimini
Rimini, Italy
-
Paris Hopital Saint Louis
Paris, France
-
Pierre Bénite CHU Lyon Sud
Lyon, France
-
Rennes CHU Pontchaillou
Rennes, France
-
Rouen Centre Henri Becquerel
Rouen, France
-
SC Ematologia Torino-Molinette
Torino, Italy
-
SC Oncoematologia Terni
Terni, Italy
-
Torino Università, Ematologia 1, AO Città della Salute e della Scienza
Torino, Italy
-
Tours CHU Bretonneau
Tours, France
-
UO Ematologia Ravenna
Ravenna, Italy
-
Vandoeuvre lès Nancy CHU Brabois
Nancy, France
Conditions
Explore the condition pages connected to this study.